Hubbry Logo
ColchicineColchicineMain
Open search
Colchicine
Community hub
Colchicine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Colchicine
Colchicine
Colchicine
View on Wikipedia
from Wikipedia

Colchicine
Skeletal formula of colchicine
Ball-and-stick model of the colchicine molecule
Clinical data
Pronunciation/ˈkɒltʃɪsiːn/ KOL-chiss-een
Trade namesColcrys, Mitigare, others
AHFS/Drugs.comMonograph
MedlinePlusa682711
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability45%
Protein binding35-44%
MetabolismMetabolism, partly by CYP3A4
Elimination half-life26.6-31.2 hours
ExcretionFeces (65%)
Identifiers
  • N-[(7S)-1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.544 Edit this at Wikidata
Chemical and physical data
FormulaC22H25NO6
Molar mass399.443 g·mol−1
3D model (JSmol)
  • CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
  • InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1 checkY
  • Key:IAKHMKGGTNLKSZ-INIZCTEOSA-N checkY
  (verify)

Colchicine is a medication used to prevent and treat gout,[3][4] to treat familial Mediterranean fever[5] and Behçet's disease,[6] and to reduce the risk of myocardial infarction.[7] The American College of Rheumatology recommends colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids in the treatment of gout.[8][9] Other uses for colchicine include the management of pericarditis.[10]

Colchicine is taken by mouth.[11] The injectable route of administration for colchicine can be toxic. In 2008, the US Food and Drug Administration removed all injectable colchicine from the US market.[12][13]

Colchicine has a narrow therapeutic index, so overdosing is a significant risk. Common side effects of colchicine include gastrointestinal upset, particularly at high doses.[14] Severe side effects may include pancytopenia (low blood cell counts) and rhabdomyolysis (damage to skeletal muscle), and the medication can be deadly in overdose.[11] Whether colchicine is safe for use during pregnancy is unclear, but its use during breastfeeding appears to be safe.[11][15] Colchicine works by decreasing inflammation via multiple mechanisms.[16]

Colchicine, in the form of the autumn crocus (Colchicum autumnale), was used as early as 1500 BC to treat joint swelling.[17] It was approved for medical use in the United States in 1961.[2] It is available as a generic medication.[15] In 2023, it was the 215th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[18][19]

Colchicine is used in plant breeding to induce polyploidy, in which the number of chromosomes in plant cells are doubled. This helps produce larger, hardier, faster-growing, and in general, more desirable plants than the normally diploid parents.[20]

Medical uses

[edit]

Gout

[edit]

Colchicine is an alternative for those unable to tolerate nonsteroidal anti-inflammatory drugs (NSAIDs) when treating gout.[21][22][23][24] Low doses (1.2 mg in one hour, followed by 0.6 mg an hour later) appear to be well tolerated and may reduce gout symptoms and pain, perhaps as effectively as NSAIDs.[25] At higher doses, side effects (primarily diarrhea, nausea, or vomiting) limit its use.[25]

For treating gout symptoms, colchicine is taken orally, with or without food, as symptoms first appear.[26] Subsequent doses may be needed if symptoms worsen.[26]

There is preliminary evidence that daily colchicine may be effective as a long-term prophylaxis when used with allopurinol to reduce the risk of increased uric acid levels and acute gout flares;[27] adverse gastrointestinal effects may occur,[28] though overall the risk of serious side effects is low.[29][30]

Risk of cardiovascular disorders

[edit]

In June 2023, the US FDA approved a low-dose regimen of colchicine (brand name Lodoco) to reduce the risk of further disorders in adults with existing cardiovascular diseases.[31][32] As an anti-inflammatory drug, Lodoco in a dose of 0.5 mg per day reduced the rate of cardiovascular events by 31% in people with established atherosclerosis and by 23% in people with recent myocardial infarction.[32] Colchicine was most effective in combination therapy with lipid-lowering and anti-inflammatory medications.[32] The mechanism for this effect of colchicine is unknown.[31]

Other conditions

[edit]

Colchicine is also used as an anti-inflammatory agent for long-term treatment of Behçet's disease.[33] It appears to have limited effect in relapsing polychondritis, as it may only be useful for the treatment of chondritis and mild skin symptoms.[34] It is a component of therapy for several other conditions, including pericarditis, pulmonary fibrosis, biliary cirrhosis, various vasculitides, pseudogout, spondyloarthropathy, calcinosis, scleroderma, and amyloidosis.[33][35][36]

Research regarding the efficacy of colchicine in many of these diseases has not been performed.[36] It is also used in the treatment of familial Mediterranean fever,[33] in which it reduces attacks and the long-term risk of amyloidosis.[37]

Colchicine is effective for prevention of atrial fibrillation after cardiac surgery.[38] In people with recent myocardial infarction (recent heart attack), it has been found to reduce risk of future cardiovascular events. Its clinical use may grow to include this indication.[39][40]

Contraindications

[edit]

Long-term (prophylactic) regimens of oral colchicine are absolutely contraindicated in people with advanced kidney failure (including those on dialysis).[26] About 10–20% of a colchicine dose is excreted unchanged by the kidneys; it is not removed by hemodialysis. Cumulative toxicity is a high probability in this clinical setting, and a severe neuromyopathy may result. The presentation includes a progressive onset of proximal weakness, elevated creatine kinase, and sensorimotor polyneuropathy. Colchicine toxicity can be potentiated by the concomitant use of cholesterol-lowering drugs.[26]

Adverse effects

[edit]

Deaths – both accidental and intentional – have resulted from overdose of colchicine.[26] Typical side effects of moderate doses may include gastrointestinal upset, diarrhea, and neutropenia.[22] High doses can also damage bone marrow, lead to anemia, and cause hair loss. All of these side effects can result from inhibition of mitosis,[41] which may include neuromuscular toxicity and rhabdomyolysis.[26]

Toxicity

[edit]

According to one review, colchicine poisoning by overdose (range of acute doses of 7 to 26 mg) begins with a gastrointestinal phase occurring 10–24 hours after ingestion, followed by multiple organ dysfunction occurring 24 hours to 7 days after ingestion, after which the affected person either declines into multiple organ failure or recovers over several weeks.[42]

Colchicine can be toxic when ingested, inhaled, or absorbed in the eyes.[22] It can cause a temporary clouding of the cornea and be absorbed into the body, causing systemic toxicity. Symptoms of colchicine overdose start 2 to 24 hours after the toxic dose has been ingested, and include burning in the mouth and throat, fever, vomiting, diarrhea, and abdominal pain.[26] This can cause hypovolemic shock due to extreme vascular damage and fluid loss through the gastrointestinal tract, which can be fatal.[42][43]

If the affected persons survive the gastrointestinal phase of toxicity, they may experience multiple organ failure and critical illness. This includes kidney damage, which causes low urine output and bloody urine; low white blood cell counts that can last for several days; anemia; muscular weakness; liver failure; hepatomegaly; bone marrow suppression; thrombocytopenia; and ascending paralysis leading to potentially fatal respiratory failure. Neurologic symptoms are also evident, including seizures, confusion, and delirium; children may experience hallucinations. Recovery may begin within six to eight days and begins with rebound leukocytosis and alopecia as organ functions return to normal.[41][42]

Long-term exposure to colchicine can lead to toxicity, particularly of the bone marrow, kidney, and nerves. Effects of long-term colchicine toxicity include agranulocytosis, thrombocytopenia, low white blood cell counts, aplastic anemia, alopecia, rash, purpura, vesicular dermatitis, kidney damage, anuria, peripheral neuropathy, and myopathy.[41]

No specific antidote for colchicine is known, but supportive care is used in cases of overdose. In the immediate period after an overdose, monitoring for gastrointestinal symptoms, cardiac dysrhythmias, and respiratory depression is appropriate,[41] and may require gastrointestinal decontamination with activated charcoal or gastric lavage.[42][43]

Mechanism of toxicity

[edit]

With overdoses, colchicine becomes toxic as an extension of its cellular mechanism of action via binding to tubulin.[42] Cells so affected undergo impaired protein assembly with reduced endocytosis, exocytosis, cellular motility, and interrupted function of heart cells, culminating in multiple organ failure.[16][42]

Epidemiology

[edit]

In the United States, several hundred cases of colchicine toxicity are reported annually, about 10% of which end with serious morbidity or mortality. Many of these cases are intentional overdoses, but others were accidental; for example, if the drug were not dosed appropriately for kidney function. Most cases of colchicine toxicity occur in adults. Many of these adverse events resulted from the use of intravenous colchicine.[36] It was used intentionally as a poison in the 2015 killing of Mary Yoder.

Drug interactions

[edit]

Colchicine interacts with the P-glycoprotein transporter, and the CYP3A4 enzyme involved in drug and toxin metabolism.[26][42] Fatal drug interactions have occurred when colchicine was taken with other drugs that inhibit P-glycoprotein and CYP3A4, such as erythromycin or clarithromycin.[26]

People taking macrolide antibiotics, ketoconazole, or cyclosporine, or those who have liver or kidney disease, should not take colchicine, as these drugs and conditions may interfere with colchicine metabolism and raise its blood levels, potentially increasing its toxicity abruptly.[26][42] Symptoms of toxicity include gastrointestinal upset, fever, muscle pain, low blood cell counts, and organ failure.[22][26] People with HIV/AIDS taking atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir may experience colchicine toxicity.[26] Grapefruit juice and statins can also increase colchicine concentrations.[26][44]

Pharmacology

[edit]

Mechanism of action

[edit]

In gout, inflammation in joints results from the precipitation of uric acid as needle-like crystals of monosodium urate in and around synovial fluid and soft tissues of joints.[16] These crystal deposits cause inflammatory arthritis, which is initiated and sustained by mechanisms involving various proinflammatory mediators, such as cytokines.[16] Colchicine accumulates in white blood cells and affects them in a variety of ways - decreasing motility, mobilization (especially chemotaxis), and adhesion.[36]

Under preliminary research are various mechanisms by which colchicine may interfere with gout inflammation:

Generally, colchicine appears to inhibit multiple proinflammatory mechanisms, while enabling increased levels of anti-inflammatory mediators.[16] Apart from inhibiting mitosis, colchicine inhibits neutrophil motility and activity, leading to a net anti-inflammatory effect, which has efficacy for inhibiting or preventing gout inflammation.[16][26]

Pharmacokinetics

[edit]

Colchicine appears to be a peripherally selective drug with limited brain uptake due to binding to P-glycoprotein.[45][46][47]

History

[edit]

The plant source of colchicine, the autumn crocus (Colchicum autumnale), was described for treatment of rheumatism and swelling in the Ebers Papyrus (circa 1500 BC), an Egyptian medical text.[48] It is a toxic alkaloid and secondary metabolite.[22][49][26] Colchicum extract was first described as a treatment for gout in De Materia Medica by Pedanius Dioscorides, in the first century AD. Use of the bulb-like corms of Colchicum to treat gout probably dates to around 550 AD, as the "hermodactyl" recommended by Alexander of Tralles. Colchicum corms were used by the Persian physician Avicenna, and were recommended by Ambroise Paré in the 16th century, and appeared in the London Pharmacopoeia of 1618.[50][36] Colchicum use waned over time, likely due[citation needed] to the severe gastrointestinal side effects preparations caused. In 1763, Colchicum was recorded as a remedy for dropsy (now called edema) among other illnesses.[36] Colchicum plants were brought to North America by Benjamin Franklin, who had gout himself and had written humorous doggerel about the disease during his stint as United States Ambassador to France.[51]

Colchicine was first isolated in 1820 by French chemists P. S. Pelletier and J. B. Caventou.[52] In 1833, P. L. Geiger purified an active ingredient, which he named colchicine.[53] It quickly became a popular remedy for gout.[36] The determination of colchicine's structure required decades, although in 1945, Michael Dewar made an important contribution when he suggested that, among the molecule's three rings, two were seven-member rings.[54] Its pain-relieving and anti-inflammatory effects for gout were linked to its ability to bind with tubulin.

The full synthesis of colchicine was achieved by the Swiss organic chemist Albert Eschenmoser in 1959.[55]

United States

[edit]

Sources and uses

[edit]

Physical properties

[edit]

Colchicine has a melting point of 142-150 °C. It has a molecular weight of 399.4 grams per mole.[56]

Structure

[edit]

Colchicine has one stereocenter located at carbon 7. The natural configuration of this stereocenter is S. The molecule also contains one chiral axis - the single bond between rings A and C. The natural configuration of this axis is aS. Although colchicine has four stereoisomers, the only one found in nature is the aS,7s configuration.[57]

Light sensitivity

[edit]

Colchicine is a light-sensitive compound, so needs to be stored in a dark bottle. Upon exposure to light, colchicine undergoes photoisomerization and transforms into structural isomers, called lumicolchicine. After this transformation, colchicine is no longer effective in its mechanistic binding to tubulin, so is not effective as a drug.[58]

Regulation

[edit]

It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002) and is subject to strict reporting requirements by facilities that produce, store, or use it in significant quantities.[59]

Formulations and dosing

[edit]

Trade names for colchicine are Colcrys or Mitigare, which are manufactured as a dark– and light-blue capsule having a dose of 0.6 mg.[26][60] Colchicine is also prepared as a white, yellow, or purple pill (tablet) having a dose of 0.6 mg.[60]

Colchicine is typically prescribed to mitigate or prevent the onset of gout, or its continuing symptoms and pain, using a low-dose prescription of 0.6 to 1.2 mg per day, or a high-dose amount of up to 4.8 mg in the first 6 hours of a gout episode.[14][26] With an oral dose of 0.6 mg, peak blood levels occur within one to two hours.[49] For treating gout, the initial effects of colchicine occur in a window of 12 to 24 hours, with a peak within 48 to 72 hours.[26] It has a narrow therapeutic window, requiring monitoring of the subject for potential toxicity.[26] Colchicine is not a general pain-relief drug, and is not used to treat pain in other disorders.[26]

Biosynthesis

[edit]

According to laboratory research, the biosynthesis of colchicine involves the amino acids phenylalanine and tyrosine as precursors. Giving radioactive phenylalanine-2-14C to C. byzantinum, another plant of the family Colchicaceae, resulted in its incorporation into colchicine.[61] However, the tropolone ring of colchicine resulted from the expansion of the tyrosine ring. Radioactive feeding experiments of C. autumnale revealed that colchicine can be synthesized biosynthetically from (S)-autumnaline. That biosynthetic pathway occurs primarily through a phenolic coupling reaction involving the intermediate isoandrocymbine. The resulting molecule undergoes O-methylation directed by S-adenosylmethionine. Two oxidation steps followed by the cleavage of the cyclopropane ring lead to the formation of the tropolone ring contained by N-formyldemecolcine. N-formyldemecolcine hydrolyzes then to generate the molecule demecolcine, which also goes through an oxidative demethylation that generates deacetylcolchicine. The molecule of colchicine appears finally after the addition of acetyl-coenzyme A to deacetylcolchicine.[62][63]

A

Purification

[edit]

Colchicine may be purified from Colchicum autumnale (autumn crocus) or Gloriosa superba (glory lily). Concentrations of colchicine in C. autumnale peak in the summer, and range from 0.1% in the flower to 0.8% in the bulb and seeds.[36]

Botanical use and seedless fruit

[edit]

Colchicine is used in plant breeding by inducing polyploidy in plant cells to produce new or improved varieties, strains, and cultivars.[20] When used to induce polyploidy in plants, colchicine cream is usually applied to a growth point of the plant, such as an apical tip, shoot, or sucker. Seeds can be presoaked in a colchicine solution before planting. Since chromosome segregation is driven by microtubules, colchicine alters cellular division by inhibiting chromosome segregation during mitosis; half the resulting daughter cells, therefore, contain no chromosomes, while the other half contains double the usual number of chromosomes (i.e., tetraploid instead of diploid), and lead to cell nuclei with double the usual number of chromosomes (i.e., tetraploid instead of diploid).[20] While this would be fatal in most higher animal cells, in plant cells, it is not only usually well-tolerated, but also frequently results in larger, hardier, faster-growing, and in general more desirable plants than the normally diploid parents. For this reason, this type of genetic manipulation is frequently used in breeding plants commercially.[20]

When such a tetraploid plant is crossed with a diploid plant, the triploid offspring are usually sterile (unable to produce fertile seeds or spores), although many triploids can be propagated vegetatively. Growers of annual triploid plants not readily propagated vegetatively cannot produce a second-generation crop from the seeds (if any) of the triploid crop and need to buy triploid seed from a supplier each year. Many sterile triploid plants, including some trees and shrubs, are becoming increasingly valued in horticulture and landscaping because they do not become invasive species and do not drop undesirable fruit and seed litter. In certain species, colchicine-induced triploidy has been used to create "seedless" fruit, such as seedless watermelons (Citrullus lanatus). Since most triploids do not produce pollen themselves, such plants usually require cross-pollination with a diploid parent to induce seedless fruit production.

The ability of colchicine to induce polyploidy can be also exploited to render infertile hybrids fertile, for example in breeding triticale (× Triticosecale) from wheat (Triticum spp.) and rye (Secale cereale). Wheat is typically tetraploid and rye diploid, with their triploid hybrid infertile; treatment of triploid triticale with colchicine gives fertile hexaploid triticale.[64]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Colchicine

View on Grokipedia
from Grokipedia
Colchicine is a naturally occurring derived from the plant Colchicum autumnale, commonly known as autumn , and has been used medicinally for over 3,500 years to treat inflammatory conditions such as . It functions primarily as an anti-inflammatory agent by binding to , thereby disrupting microtubule polymerization and inhibiting key inflammatory processes, including neutrophil chemotaxis, inflammasome activation, and the release of proinflammatory cytokines like interleukin-1β. The U.S. (FDA) has approved colchicine for the prophylaxis and treatment of acute flares in adults, as well as for the prevention of attacks in those with (FMF), a genetic autoinflammatory disorder, and for reducing the risk of , , coronary , and cardiovascular death in adults with established atherosclerotic . Historically, colchicine's therapeutic use dates back to around 1500 BCE, as documented in the for alleviating joint pain, and it was later purified in the early before gaining modern regulatory approval in 2009. Pharmacologically, it exhibits rapid absorption with a of approximately 45%, undergoes hepatic metabolism primarily via , and has an elimination of 26.6 to 31.2 hours, necessitating dose adjustments in patients with renal or hepatic impairment to avoid toxicity. Beyond its established indications, colchicine has off-label applications in managing recurrent and treating dermatological conditions like and Sweet's syndrome, reflecting its broad modulation of innate immune responses. Common adverse effects include gastrointestinal disturbances such as (affecting up to 23% of users), , and , while severe risks like or can occur with overdose or drug interactions.

Chemical Properties

Structure

Colchicine has the molecular formula C₂₂H₂₅NO₆ and features a structure composed of three distinct rings: ring A, a trimethoxybenzene ring; ring B, a seven-membered ring; and ring C, a ring. This arrangement forms a benzoheptalene core, with ring A attached to ring B via a and ring C fused to ring B, contributing to the molecule's rigidity and planarity in certain conformations. Ring A is characterized by three methoxy groups at positions 1, 2, and 3, providing electron-donating s that influence the aromatic system's reactivity. Ring B includes an acetamido group (-NHCOCH₃) at the 7-position and connects the other rings, while ring C, the moiety, incorporates a seven-membered ring with a hydroxyl group and a , enabling resonance stabilization through a freely resonating between the oxygen and a methyl . Key functional groups, such as the acetamido on ring B and the methoxy groups on ring A, are integral to the molecule's overall architecture. The of colchicine includes a chiral center at carbon-7 on ring B with an (S)-configuration and an axis of between rings A and C, designated as (aS), arising from a approximately 53° twist in the biaryl linkage. The moiety in ring C features this specific stereochemical arrangement, which defines the molecule's three-dimensional profile. In 2D representations, colchicine is typically depicted with ring A at the top, ring B in the middle as a puckered seven-membered ring, and ring C at the bottom showing the enol-keto tautomerism of the . 3D models reveal a non-planar conformation, with the acetamido group oriented axially relative to ring B and the ring exhibiting partial due to delocalized electrons. Structurally, colchicine is related to other tropolone alkaloids, such as demecolcine, by sharing the characteristic ring C but differing in the substitution patterns on rings A and B, including the presence of an additional in colchicine. This unique system distinguishes it from simpler tropolones like those found in unrelated natural products.

Physical Properties

Colchicine appears as a pale to white crystalline powder or needles, which is odorless or nearly odorless. It has a of 145–150 °C, often with . Colchicine exhibits poor in , with approximately 1 g dissolving in 22–25 mL at , while it is freely soluble in alcohol (e.g., 50 mg/mL in ) and . Its , expressed as logP, is approximately 1.3, indicating moderate that influences its distribution in formulations. Regarding stability, colchicine is sensitive to extremes and elevated temperatures, with slow occurring in acidic conditions to yield degradation products such as colchiceine. It remains stable in neutral or slightly alkaline unbuffered solutions ( around 5.9–8.1) and at (e.g., 20–68 °F) for at least six months, though decomposition accelerates above its .

Light Sensitivity

Colchicine is highly sensitive to light, undergoing primarily through the moiety in its . Exposure to (UV) light triggers a concerted disrotatory 4π electrocyclization reaction, resulting in ring opening and the formation of inactive lumicolchicine isomers, such as α-, β-, and γ-lumicolchicine. This process deactivates the compound's , as the lumicolchicines lack the microtubule-binding properties of colchicine. The sensitivity arises from colchicine's absorption spectrum, with key bands at approximately 245 nm and 350 nm, corresponding to π–π* and n–π* transitions that excite the to the S1 state, facilitating the . While direct or UV sources accelerate this reaction, even ambient artificial light contributes to gradual degradation. The kinetics follow pseudo-first-order behavior, with rate constants influenced by solvent polarity and ; for instance, in acidic conditions, the conversion yield can drop to 40% from a maximum of 90% under optimal . Due to this instability, pharmaceutical guidelines recommend storing colchicine in airtight, light-resistant containers, such as amber glass vials, and protecting solutions from direct or indirect exposure to maintain potency. In practice, unprotected solutions under fluorescent may exhibit around 10% degradation over 24 hours, underscoring the need for opaque in formulations. Studies under UV exposure confirm measurable loss, with approximately 6.28% degradation observed in 24 hours, highlighting the importance of these precautions for long-term stability.

Biosynthesis and Sources

Biosynthesis

Colchicine biosynthesis in commences with the L-tyrosine and L-phenylalanine, which are derived from the . L-tyrosine is decarboxylated to , while L-phenylalanine is converted to 4-hydroxydihydrocinnamaldehyde (4-HDCA) via and reduction steps. These precursors undergo a Pictet-Spengler condensation to form the core 1-phenethylisoquinoline scaffold, followed by sequential N- and O-methylations, hydroxylations, and oxidative cyclizations to yield autumnaline as a key intermediate. From autumnaline, the pathway proceeds through para-ortho' phenol coupling, further cyclization to form a seven-membered ring via oxidative ring expansion, oxidative demethylation to deacetylcolchicine, and final N-acetylation to produce colchicine. This enzymatic route, elucidated through transcriptomics, , and in , highlights the plant's unique capacity for tropolone formation without direct involvement of modular synthases, though polyketide-like condensations occur in early skeleton building. Recent advances include modular assembly of biocatalytic cascades to produce pathway intermediates like (S)-autumnaline, enabling streamlined engineering for higher yields. Key enzymes in the pathway include autumnaline synthase (e.g., GsOMT3 from ), a catechol O-methyltransferase homolog that catalyzes the and coupling to form autumnaline from the precursor. Subsequent steps involve monooxygenases such as GsCYP75A109 for regioselective and GsCYP75A110 for phenolic coupling, leading to O-methylandrocymbine. Ring expansion to N-formyldemecolcine is mediated by GsCYP71FB1, followed by demethylation; demecolcine O-methyltransferase (e.g., GsOMT4, another COMT homolog) then facilitates the reverse at a later stage to refine the structure. These enzymes, part of a 16-enzyme cascade encoded by at least eight dedicated genes, enable the complex rearrangements characteristic of colchicine. Biosynthesis is predominantly localized in the corms (bulbs) and seeds of , where and accumulation are highest, reflecting adaptations for storage and dispersal in this autumn-blooming geophyte. Enzymes like the double-bond reductase CaDBR1, involved in generating 4-HDCA, show peak transcription in corms, supporting tissue-specific production. Genetically, the pathway is governed by a cluster of genes including COMT homologs (e.g., GsOMT1–GsOMT4 for methylations) and N-methyltransferase (GsNMT), with variations in expression influencing yield; for instance, natural low abundance in plants (0.1–0.5% dry weight) can be enhanced tenfold through targeted mutations like truncation of GsNMT in engineered systems. These genetic insights, derived from and transcriptomes, underscore the potential for to boost production while revealing evolutionary conservation across .

Natural Sources

Colchicine is primarily derived from the corms of plants in the family, with the most significant sources being Colchicum autumnale (commonly known as meadow saffron or autumn crocus), (glory lily), and Colchicum speciosum. In C. autumnale, colchicine concentrations in the dry corms typically range from 0.3% to 0.5%, while in G. superba tubers and seeds, levels vary between 0.2% and 0.7%. For C. speciosum, colchicine is present in both corms and seeds, though at generally lower concentrations compared to C. autumnale, making it a less common commercial source. Colchicum species, including C. autumnale and C. speciosum, are native to regions spanning Europe, North Africa, and Asia, thriving in meadows, woodlands, and mountainous areas with temperate climates. G. superba is distributed across tropical Africa, India, and Southeast Asia, often in scrublands and forest edges. Wild harvesting of these plants poses significant toxicity risks due to colchicine's potent effects; all parts, especially corms and seeds, can cause severe gastrointestinal distress, organ failure, or death if ingested accidentally, with historical cases of misidentification leading to fatalities during foraging. Colchicine occurs in minor amounts in other genera related to Colchicum, such as Androcymbium and Merendera, where it is found alongside related alkaloids like demecolcine, though these are not primary commercial sources due to lower yields and limited distribution. Historically, collection involved seasonal harvesting of corms, typically in late summer or autumn after flowering, a practice dating back to ancient medicinal uses in regions like the Mediterranean, where dried corms were gathered manually from wild populations for therapeutic preparations.

Purification

Colchicine is typically isolated from plant material such as the corms or seeds of through a series of extraction and purification steps designed for both and industrial scales. The process begins with drying and powdering the plant material to facilitate solvent penetration. Solvent extraction is then employed, commonly using or to dissolve the from the powdered tissue. To enhance solubility and selectivity, the extraction often involves acidified solvents, such as adjusted to a low pH with , which protonates the and improves its partitioning into the organic phase. Following initial extraction, the mixture is filtered, and the solvent is concentrated under reduced pressure. Acidification of the aqueous residue with dilute acid, such as acetic acid, further aids in precipitating impurities while solubilizing colchicine for subsequent organic solvent re-extraction. Purification proceeds via chromatographic techniques and to achieve high purity. on is widely used, with elution gradients of chloroform-methanol or dichloromethane-methanol mixtures allowing separation of colchicine from co-extracted compounds. Fractions are monitored by (TLC) or UV at 254 nm to identify colchicine-rich eluates, which are then pooled and evaporated. Final purification involves from or , yielding colorless to pale yellow needles of colchicine. (HPLC) is routinely applied for analytical verification and preparative polishing, ensuring purity levels exceeding 98%. Yields from dry corms typically range from 0.1% to 0.5% by weight, depending on plant variety, timing, and extraction efficiency, with higher values (up to 0.8%) possible from . Industrial processes may incorporate as an alternative to traditional solvents for improved yields and reduced environmental impact, but solvent-based methods remain standard for lab-scale isolation. A key challenge in purification is the separation of colchicine from structurally similar alkaloids, such as demecolcine, which co-occur in species and can contaminate fractions due to overlapping polarities. This requires optimized chromatographic conditions or selective precipitation to minimize impurities, as incomplete separation may affect therapeutic efficacy and safety.

Medical Uses

Gout

Colchicine serves as a cornerstone therapy for managing acute flares and preventing recurrent episodes in patients with , a form of triggered by monosodium urate crystal deposition. In the context of , colchicine specifically targets the inflammatory response induced by urate crystals, inhibiting neutrophil , , and migration to the affected while also suppressing activation, which reduces the release of interleukin-1β and subsequent amplification of inflammation. This mechanism interrupts the cascade of urate crystal-induced inflammation without directly lowering serum urate levels, distinguishing its role from urate-lowering therapies. For acute gout flare treatment, the standard dosing regimen involves an initial oral dose of 1.2 mg followed by 0.6 mg one hour later, with a total maximum of 1.8 mg over the first hour; therapy may continue at lower doses (0.5–0.6 mg twice daily) for up to 48 hours after flare resolution to sustain effects. For prophylaxis, particularly during initiation of urate-lowering therapy or in patients with frequent flares, colchicine is administered at 0.6 mg once or twice daily, not exceeding 1.2 mg per day, to mitigate the risk of mobilization flares. Clinical efficacy of colchicine in is well-established, with low-dose regimens demonstrating reduction comparable to higher doses in randomized trials, such as the AGREE study, where approximately one-third of patients achieved at least a 50% decrease in at 24 hours post-onset. The U.S. Food and Drug Administration approved colchicine (as Colcrys) in 2009 for both acute treatment and prophylaxis of gout flares based on this , marking its transition from unapproved use to standardized therapy. Recent 2025 clinical guidelines, including those from the Irish Society of Rheumatology, emphasize colchicine's role in combination with urate-lowering therapy, recommending its prophylactic use for at least the first six months after starting agents like to prevent flares triggered by urate crystal mobilization, thereby supporting long-term control.

Familial Mediterranean Fever

Colchicine serves as the first-line prophylactic therapy for (FMF), an autosomal recessive autoinflammatory disorder caused by mutations in the gene, leading to recurrent episodes of fever, , and potential systemic complications. Following its initial demonstration of efficacy in suppressing FMF attacks in a 1972 case series, colchicine has remained the cornerstone of management, dramatically improving by mitigating inflammatory flares and averting long-term sequelae. In individuals carrying MEFV mutations, colchicine prophylaxis reduces attack frequency by 80–90%, with complete remission achieved in approximately 60–65% of patients and partial remission in an additional 30%. Long-term observational studies have substantiated its protective effects against amyloid A (AA) , the most severe FMF complication, which historically caused renal failure in up to 25% of untreated cases; colchicine prevents new-onset in high-risk populations and stabilizes or reverses early renal involvement when initiated promptly. A 2025 global survey and further affirmed colchicine's high efficacy in flare prevention across diverse cohorts, with meta-analytic evidence supporting its sustained benefits over decades of use. Adult dosing typically begins at 1 mg daily, titrated to 1–2 mg administered in one or two divided doses based on clinical response and gastrointestinal tolerance, with a maximum of 3 mg daily in compliant patients. For pediatric patients, initial doses are age-adjusted—0.5 mg/day for those under 5 years, 1 mg/day for ages 5–10 years, and 1.5 mg/day for those over 10 years—or equivalently 0.5–1.5 mg/m² daily, not exceeding 2 mg total per day to minimize toxicity risks. Colchicine resistance occurs in 5–10% of FMF patients, characterized by ≥3 attacks per year despite adherence to maximum tolerated doses (≥1.5 mg/day in adults). This non-response is frequently attributed to genetic factors, including homozygous MEFV mutations such as p.M694V, which correlate with heightened inflammasome activity and more refractory disease courses. Management of resistant cases involves escalating to biologic agents targeting interleukin-1 pathways.

Pericarditis and Cardiovascular Risk Reduction

Colchicine is used as an adjunct therapy for acute and recurrent pericarditis, where it significantly reduces the risk of recurrence when added to standard anti-inflammatory treatments such as aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). In the Investigational Colchicine for Acute Pericarditis (ICAP) trial, a randomized, double-blind study involving 240 patients, colchicine at a dose of 0.5 mg twice daily for three months reduced the incidence of incessant or recurrent pericarditis at 18 months from 37.5% in the placebo group to 16.7%, representing a relative risk reduction of approximately 55%. Similarly, the Colchicine for Recurrent Pericarditis (CORP) trial demonstrated that colchicine halved the recurrence rate at 18 months (24% versus 55% with placebo) in 120 patients with a first episode of acute pericarditis. These findings establish colchicine's role in preventing symptom persistence and multiple recurrences, with the recommended dosing regimen of 0.5 mg twice daily for the initial three months, followed by tapering if tolerated. In cardiovascular risk reduction, colchicine has shown efficacy in secondary prevention among patients with recent myocardial infarction (MI) or stable coronary artery disease (CAD). The Colchicine Cardiovascular Outcomes Trial (COLCOT), a randomized, placebo-controlled study of 4,745 patients post-MI, found that low-dose colchicine (0.5 mg daily) reduced the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent coronary revascularization by 23% (5.3% versus 6.9% event rate; hazard ratio 0.77, 95% CI 0.61-0.96) over a median follow-up of 22.6 months. The Low-Dose Colchicine 2 (LoDoCo2) trial, involving 5,522 patients with chronic CAD, reported a 31% relative reduction in the primary endpoint of cardiovascular death, MI, ischemic stroke, or ischemia-driven revascularization (5.8% versus 7.6%; hazard ratio 0.69, 95% CI 0.57-0.83) with the same 0.5 mg daily dose over 28.6 months. These trials highlight colchicine's benefit in reducing ischemic events by 25-30% overall in high-risk populations, without increasing non-cardiovascular mortality. In 2023, the U.S. Food and Drug Administration approved low-dose colchicine (Lodoco, 0.5 mg daily) for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple coronary heart disease risk factors. Recent guidelines reflect these evidence-based outcomes, endorsing low-dose colchicine for secondary prevention in high-risk patients. The 2024 (ESC) guidelines for chronic coronary syndromes upgraded the recommendation for colchicine (0.5 mg daily) to class IIa for reducing cardiovascular events in patients with stable CAD, particularly those with residual inflammatory risk. This aligns with meta-analyses confirming a consistent 25% reduction in across trials, driven by fewer MIs and revascularizations. Colchicine's effects contribute to these benefits by stabilizing atherosclerotic plaques, as evidenced by reductions in plaque and in clinical and preclinical studies.

Other Conditions

Colchicine has been employed in the management of , particularly for controlling mucocutaneous manifestations such as oral ulcers and for mitigating flares. A daily dose of 1 mg has been shown to reduce the frequency of flares, including oral and genital ulcers, with evidence from clinical guidelines supporting its role as an initial therapy alongside nonsteroidal anti-inflammatory drugs. In cases of ocular involvement, colchicine at 1.2 mg daily has demonstrated efficacy in achieving remission of and preventing recurrences when used early. For pseudogout, also known as deposition (CPPD) disease, colchicine is used off-label to treat acute crystal-induced , mirroring its application in due to similar inflammatory pathways. Low-dose regimens effectively alleviate and reduce the number of flares in CPPD patients, with comparative trials indicating equivalence to short-course in controlling acute attacks. Investigational applications of colchicine include , where it has been explored for its potential anti- effects in preclinical and clinical trials. Although older randomized trials suggested modest improvements in liver and biochemical markers of , a comprehensive Cochrane review found no significant impact on clinical outcomes such as survival or disease progression. In , the RECOVERY trial in 2021 reported no overall clinical benefit from colchicine in hospitalized patients. However, 2025 subgroup analyses from subsequent studies indicate potential advantages in managing hyperinflammation among patients not receiving corticosteroids, highlighting its role in specific high-risk subsets. Regarding , evidence remains limited, with a 2023 systematic review and of over 6,900 patients suggesting modest reductions in and improvements in function for hand and involvement, though larger trials like the COLOR study showed no significant superiority over .

Pharmacology

Mechanism of Action

Colchicine primarily targets , the subunit that polymerizes to form , essential components of the involved in intracellular transport, , and motility. It binds specifically to the β-tubulin subunit at the colchicine-binding site, located at the interface between α- and β-tubulin heterodimers, thereby inhibiting microtubule polymerization. This binding stabilizes tubulin in a curved conformation that prevents longitudinal interactions necessary for microtubule assembly. The disruption of microtubule dynamics by colchicine leads to several downstream anti-inflammatory effects. In neutrophils, it impairs and migration by interfering with microtubule-dependent processes such as granule release and shape changes required for directed movement toward inflammatory sites. Additionally, colchicine inhibits the , a multiprotein complex that senses cellular damage and activates caspase-1, resulting in the processing and secretion of pro-inflammatory interleukin-1β (IL-1β). This occurs through microtubule disruption, which hinders the spatial organization and assembly of inflammasome components like and ASC (apoptosis-associated speck-like protein containing a CARD). Colchicine's actions are dose-dependent, reflecting varying concentrations achieved in therapeutic versus toxic ranges. At low doses (0.5–1 mg), it predominantly exerts effects by selectively modulating dynamics without complete , thereby targeting inflammatory pathways like recruitment and activation. At higher doses, it induces more profound , leading to mitotic arrest during by preventing the formation of the mitotic spindle. This selectivity arises from colchicine's reversible binding to , which does not affect other cytoskeletal elements such as filaments or intermediate filaments, ensuring specificity to microtubule-related functions.

Pharmacokinetics

Colchicine exhibits characteristic pharmacokinetic properties that influence its therapeutic use and safety profile. Following , the drug is rapidly absorbed from the , primarily in the and , with an absolute of approximately 45%. Peak plasma concentrations (T_max) are achieved within 0.5 to 2 hours in healthy adults, and while food intake may delay absorption by about 1 hour, it has no effect on the rate or extent of colchicine absorption. The drug is widely distributed throughout the body, with a (V_d) ranging from 5 to 8 L/kg in healthy young adults, reflecting extensive tissue penetration including accumulation in leukocytes. Colchicine demonstrates low (approximately 40% to ) and readily crosses the , potentially exposing the during . Penetration into the (CSF) is limited, with a normal CSF-to-serum ratio of less than 10%, likely due to efflux transport mechanisms at the blood-brain barrier. Metabolism of colchicine occurs primarily in the liver and intestines via the 3A4 () enzyme system, with involvement of (P-gp) efflux transporters that limit intracellular accumulation. The major metabolites include 2-O-demethylcolchicine and 3-O-demethylcolchicine, which are largely inactive and contribute minimally to the drug's pharmacological effects. Elimination of colchicine is predominantly fecal via biliary excretion, with only 10% to 20% of the dose excreted unchanged in the urine, indicating limited renal clearance. In healthy adults, the terminal elimination is approximately 20 to 30 hours following multiple doses, though single-dose may be shorter (around 4 to 9 hours). Renal impairment significantly prolongs the (e.g., up to 18.8 hours in end-stage renal disease) and reduces clearance by about 75%, necessitating dose adjustments to avoid accumulation.

Clinical Considerations

Formulations and Dosing

Colchicine is primarily available in oral s, including tablets of 0.5 mg and 0.6 mg strengths, as well as capsules and oral solutions in generic forms. In 2023, the FDA approved a 0.5 mg tablet (Lodoco) specifically for reducing cardiovascular risk in adults with established atherosclerotic . An intravenous was previously used but has been discontinued in many countries, including the , due to risks of severe and lack of approved applications. As of 2025, generic availability has expanded to include colchicine capsules (0.6 mg) and oral solutions (0.6 mg/5 mL), improving accessibility for prophylaxis. products with uricosurics, such as probenecid (500 mg) and colchicine (0.5 mg) tablets, are also available for chronic management. General dosing guidelines recommend 0.5 to 1.2 mg per day in divided doses for prophylaxis in adults, with a maximum of 1.2 mg daily to minimize risks. For acute treatment, the regimen is typically 1.2 mg initially followed by 0.6 mg one hour later, not exceeding 1.8 mg total in the first 24 hours. These doses assume normal renal and hepatic function, with without regard to meals. Dose adjustments are required for organ impairment and age-related factors. In renal impairment with creatinine clearance less than 30 mL/min, halve the dose for prophylaxis (e.g., 0.3 mg daily) and limit acute dosing to a single 0.6 mg dose without repetition for at least two weeks. For hepatic impairment classified as Child-Pugh B or C, avoid use if possible or consider significant dose reduction, such as limiting to 0.3 mg every other day for prophylaxis, due to prolonged exposure. In elderly patients, reduce the dose by approximately 50% or base it strictly on renal function to account for diminished clearance.

Drug Interactions

Colchicine undergoes metabolism primarily via the 3A4 () enzyme and is a substrate for the (P-gp) efflux transporter, rendering it susceptible to significant pharmacokinetic interactions with drugs that inhibit or induce these pathways. These interactions can markedly alter colchicine plasma concentrations, potentially leading to from elevated levels or reduced efficacy from lowered exposure. Life-threatening and fatal outcomes have been reported, particularly when strong or P-gp inhibitors are coadministered, especially in patients with renal or hepatic impairment. Strong inhibitors, such as and , substantially increase colchicine exposure; for instance, elevates the area under the curve (AUC) by approximately 3.8-fold and maximum concentration (Cmax) by 3.3-fold, while increases AUC by about 3.1-fold and Cmax by 2.0-fold. Such interactions contraindicate colchicine use in patients with renal or hepatic impairment, and in others, dosing must be reduced by up to 75%—for flares, limited to a single 0.6 mg dose followed by 0.3 mg one hour later (with no repeat for at least three days), and for (FMF), a maximum daily dose of 0.6 mg. Moderate CYP3A4 inhibitors like verapamil also raise colchicine levels (AUC increase of ~2.0-fold), necessitating dose reductions to 50% of standard (e.g., maximum 1.2 mg/day for FMF) and close monitoring for neuromuscular toxicity. P-gp inhibitors, including cyclosporine, similarly amplify colchicine concentrations (AUC increase of ~3.6-fold with cyclosporine), carrying risks of severe toxicity and requiring the same contraindications and dose adjustments as strong inhibitors. Verapamil, as a dual moderate and P-gp inhibitor, heightens the risk of when combined with colchicine. inducers such as rifampin substantially decrease colchicine exposure by accelerating its metabolism and efflux, potentially compromising therapeutic ; case reports document low colchicine levels in patients on rifampin, and coadministration should be avoided if possible, with dose increases and monitoring considered if necessary, noting that induction effects may take 1–2 weeks to onset or offset. Among common coadministered drugs, statins (e.g., , simvastatin) potentiate the risk of and when used with colchicine due to shared pathways and pharmacodynamic effects; patients should be monitored for muscle pain or weakness, with discontinuation if symptoms arise. Coadministration with , another P-gp substrate, may increase the risk of additive toxicity including and , though pharmacokinetic changes are modest (23% increase in colchicine AUC); close monitoring is advised, and alternatives should be considered where feasible.
Interacting Drug Class/ExamplesMechanismEffect on ColchicineManagement Recommendations
Strong CYP3A4 inhibitors (e.g., , )Inhibition of 3–4-fold ↑ AUC/CmaxContraindicated in renal/hepatic impairment; reduce dose 75% otherwise; monitor for toxicity
P-gp inhibitors (e.g., cyclosporine)Inhibition of efflux~3.6-fold ↑ AUCSame as strong CYP3A4 inhibitors
CYP3A4 inducers (e.g., rifampin)Induction of /effluxSubstantial ↓ exposureAvoid if possible; monitor efficacy and consider dose increase
Statins (e.g., )Pharmacodynamic interaction↑ risk of Monitor for ; discontinue if symptoms occur
P-gp competition; pharmacodynamicPotential additive toxicity ()Monitor closely; consider alternatives

Contraindications

Colchicine is contraindicated in severe renal impairment (e.g., CrCl <15 mL/min for certain indications like cardiovascular risk reduction), particularly when coadministered with or inhibitors, owing to substantial drug accumulation and heightened risk of , as the medication is primarily eliminated via the kidneys. Severe hepatic impairment represents another absolute , particularly in combination with (P-gp) or strong inhibitors, due to impaired metabolism and clearance leading to life-threatening adverse effects. The drug is also contraindicated in individuals with blood dyscrasias, including conditions like , , or , as colchicine can further suppress function and exacerbate these disorders. In pregnancy, available data from studies in pregnant women have not identified an increased risk of major birth defects, , or adverse maternal or fetal outcomes with colchicine use; however, animal studies have shown embryofetal at high doses, and use should be based on a benefit-risk assessment. Relative contraindications encompass advanced age, where elderly patients face an elevated risk of neuromuscular and even with preserved renal and hepatic function, necessitating careful dose adjustment and monitoring. Patients with preexisting gastrointestinal disorders, such as peptic ulcers or , require cautious use, as colchicine may aggravate mucosal irritation and permeability issues. Concurrent administration with strong inhibitors is relatively contraindicated in those with any renal or hepatic impairment, amplifying exposure and toxicity risks. Among special populations, colchicine should be avoided in neonates due to their immature renal and hepatic clearance pathways, which predispose to overdose. For breastfeeding individuals, the drug passes into in low amounts—resulting in infant exposure of less than 10% of the maternal weight-adjusted dose—but infants should be monitored for potential gastrointestinal disturbances or . Genetic polymorphisms in ABCB1 may influence colchicine response and toxicity, particularly in FMF, potentially requiring dose adjustments based on individual factors.

Adverse Effects and Toxicity

Adverse Effects

Colchicine therapy is commonly associated with gastrointestinal adverse effects, which are the most frequent side effects encountered at therapeutic doses and often serve as the dose-limiting factor. occurs in 10–23% of patients, while and affect up to 20%, typically presenting as mild, transient symptoms that resolve upon dose reduction or discontinuation. Hematologic effects are less common but can be serious, including and , reported in less than 1% of cases based on ; these are generally reversible with prompt discontinuation of the drug. Musculoskeletal adverse effects include , occurring in approximately 21% of patients in cardiovascular trials, and rare instances of estimated at 0.1%; these risks may be heightened in the presence of renal impairment or concurrent use but are reversible upon cessation. Other reported effects at therapeutic doses encompass alopecia and , both observed infrequently in postmarketing reports and typically reversible. To mitigate risks, monitoring with (CBC) for hematologic effects and (CK) levels for musculoskeletal symptoms is recommended, particularly in patients with renal or hepatic impairment.

Toxicity Overview

Colchicine toxicity typically arises from acute overdose or chronic accumulation during high-dose therapy, presenting as a life-threatening condition with a narrow . In cases of acute , progresses through three overlapping phases. The initial gastrointestinal phase occurs 2 to 24 hours post-, characterized by severe , , watery , and , leading to significant fluid and losses. This is followed by a multi-organ phase from 24 to 72 hours, involving , with , renal insufficiency, hepatic dysfunction, cardiac arrhythmias, and neuromuscular weakness, which can culminate in , , and death. A recovery phase may ensue after 7 days in survivors, marked by rebound and gradual resolution of organ damage, though long-term sequelae such as alopecia or neuropathy can persist. The oral (LD50) of colchicine in humans is estimated at approximately 0.5 to 0.8 mg/kg, with ingestions exceeding 0.5 mg/kg carrying a high fatality rate; the lowest reported lethal doses range from 7 to 26 mg in adults. Chronic toxicity develops insidiously from cumulative exposure in prolonged high-dose regimens, such as for or , manifesting with progressive gastrointestinal symptoms, , and multi-organ effects similar to acute poisoning but with slower onset and potentially reversible outcomes upon dose adjustment. Management of colchicine toxicity relies on early and aggressive supportive care, as no specific exists. For acute ingestions within 1 to 2 hours, administration of activated charcoal (1 g/kg) or is recommended to reduce absorption, followed by intravenous fluid resuscitation to address and imbalances. Patients require intensive monitoring for at least 24 to 48 hours, including serial complete blood counts, renal and hepatic function tests, and ; may be used to mitigate severe during the multi-organ phase. Experimental therapies like colchicine-specific Fab fragments have shown promise in animal models and isolated cases but are not commercially available. For chronic cases, prompt dose reduction and discontinuation typically suffice, with supportive measures as needed.

Mechanism of Toxicity

Colchicine exerts its toxic effects primarily through high-affinity binding to tubulin subunits, forming a colchicine-tubulin complex that prevents and disrupts the microtubular network essential for cellular functions. At concentrations exceeding 10 μM, this binding leads to profound mitotic arrest, particularly in rapidly dividing cells, by inhibiting spindle formation during . In the gastrointestinal mucosa, where epithelial cells exhibit high turnover, this mitotic inhibition causes arrest, increased apoptotic bodies in crypts, and subsequent epithelial , resulting in mucosal sloughing and breakdown of the intestinal barrier. Systemically, the antimitotic action extends to other proliferative tissues, amplifying toxicity beyond the . In the bone marrow, colchicine's disruption of microtubule-dependent processes halts hematopoiesis, leading to suppression of myeloid and erythroid lineages and subsequent , which manifests days after exposure. Similarly, in cardiac myocytes, microtubule impairs cytoskeletal integrity, contractility, and conduction, contributing to and cardiovascular collapse as part of multiorgan dysfunction. These effects culminate in widespread cellular dysfunction, including impaired , , and motility, exacerbating systemic failure. A paradoxical aspect of colchicine toxicity involves its interaction with the pathway, where low therapeutic doses suppress activation to mitigate , but toxic doses trigger a rebound pro-inflammatory response. High concentrations induce massive cell from mitotic arrest and , releasing damage-associated molecular patterns (DAMPs) and endogenous toxins, which overactivate the and provoke a characterized by elevated IL-1β, IL-6, and TNF-α levels. This rebound , compounded by gut barrier disruption and endotoxemia, drives and multiorgan failure, contrasting sharply with the drug's benefits at sub-toxic levels. The shift from therapeutic to toxic effects hinges on a narrow dose threshold, where plasma concentrations below 3 ng/mL selectively target activated neutrophils via disruption without widespread mitotic inhibition, preserving efficacy. Above 10-20 ng/mL, however, colchicine overwhelms reserves in all dividing cells, transitioning from targeted suppression to indiscriminate pro-apoptotic and cytotoxic actions that dominate the toxic profile.

Epidemiology of Toxicity

Colchicine toxicity remains a significant concern globally, though reported cases are relatively uncommon compared to other pharmaceuticals. In the United States, poison control centers document approximately 1,800 exposures to colchicine annually, with around 1,100 involving single-substance ingestions, based on 2020 data from the National Poison Data System (NPDS). Severe toxicity, characterized by multi-organ , occurs in roughly 2-3% of reported cases, often leading to substantial morbidity or death. Among therapeutic users, the incidence of severe toxicity is estimated at 1-2%, primarily due to the drug's narrow , though exact rates vary with dosing adherence and comorbidities. As of 2023, NPDS data continues to reflect stable trends in exposures and outcomes, with ongoing monitoring recommended for updates. Risk factors for colchicine poisoning include intentional overdose, which accounts for about 20% of cases and is frequently linked to suicidal intent. Accidental exposures are common in elderly patients with , often resulting from therapeutic errors or inappropriate dosing in the context of renal impairment. Plant ingestion, particularly from or , contributes to cases worldwide, with the latter prevalent in self-poisoning scenarios. Mortality in severe cases stands at approximately 10%, though overall fatality rates have declined following heightened awareness from 2009 FDA warnings on dosing and interactions, which reduced misuse of unapproved formulations. Recent trends indicate a rise in colchicine-related poisonings from herbal misuse in , where tubers are used in or as suicidal agents, leading to increased reports of . In 2022, the NPDS recorded 7 colchicine-related fatalities in the , underscoring persistent risks despite preventive measures. Pediatric exposures are rare but carry high fatality rates, often exceeding 15% due to lower body weight and delayed recognition, as seen in isolated case series from and the West. These patterns highlight the need for targeted on safe use in vulnerable populations.

History

Early History and Traditional Use

Colchicine, the active derived from the autumn (Colchicum autumnale), has roots in ancient medicinal practices dating back to approximately 1500 BC in . The , one of the oldest known medical texts, describes the use of the plant for alleviating pain and swelling associated with joint conditions. By the 1st century AD, Greek physician Pedanius Dioscorides documented the therapeutic application of for treating in his seminal work , recommending it as a remedy for podagra while cautioning against its potent effects. This text, which served as a foundational pharmacopeia in the ancient world, highlighted the plant's efficacy in reducing inflammatory symptoms, though its exact mechanism remained empirical. In medieval Arabic and Byzantine medicine, the plant was known as "hermodactyl" and employed for conditions such as dropsy () and , as noted in texts by physicians like Serapion the Elder, who equated it with remedies for joint inflammation and fluid retention. These writings built on classical knowledge, integrating the into formulations for arthritic pains, often balancing its benefits against risks of overdose. Early awareness of its was evident, with Dioscorides and subsequent authors reporting fatal poisonings from excessive ingestion or confusion of Colchicum bulbs with edible plants like , leading to severe gastrointestinal distress and multi-organ failure. Prior to the , European folk traditions utilized in remedies, particularly as an emetic to induce vomiting for due to its purgative properties. These applications reflected a cautious empirical approach, with healers emphasizing precise dosing to avoid lethal outcomes, as documented in regional pharmacopeias and oral traditions.

Modern Developments

Colchicine was first isolated in 1820 by French chemists Pierre-Joseph Pelletier and Joseph Bienaimé Caventou from the autumn crocus plant, , marking a pivotal advancement in chemistry. This extraction enabled the purification of the active compound, which was fully elucidated structurally in 1945 by Michael Dewar through chemical analysis, with later confirmation via and spectroscopic methods in the mid-20th century. The isolation laid the groundwork for targeted pharmacological research, shifting colchicine from crude extracts to a defined therapeutic agent. In , clinical observations and early studies confirmed colchicine's efficacy in managing , with low doses advocated for long-term prophylaxis to prevent acute attacks. These findings built on prior empirical use, establishing colchicine as a standard intervention for reducing flare frequency without significantly altering levels. By the 1960s, colchicine's antimitotic properties—arresting cells in by binding —gained prominence in research, facilitating chromosome visualization and analysis in . This application revolutionized studies of chromosomal abnormalities, including in human karyotyping, and extended colchicine's utility beyond into basic science. The 1970s brought a major breakthrough with the discovery that daily colchicine prevents attacks in (FMF), an autoinflammatory disorder, as demonstrated in initial case reports and subsequent randomized controlled trials linking treatment response to the disease's periodic fevers. This responsiveness underscored colchicine's anti-inflammatory mechanism via inhibition. In 1997, positional cloning identified the on 16p13 as the cause of FMF, encoding pyrin and explaining colchicine's targeted efficacy in carriers. From the 2000s onward, trials initiated exploration of colchicine in , prompted by its broad anti-inflammatory effects. Landmark studies, such as the LoDoCo trial starting in 2008, showed low-dose colchicine reduced in patients with stable coronary disease by targeting residual inflammation. In 2020, retrospectives commemorated 200 years since its isolation, emphasizing colchicine's evolution from a botanical extract to a versatile agent in modern medicine, including ongoing applications in post-myocardial infarction prevention. Recent approvals, including Lodoco in 2023 for cardiovascular risk reduction and updated labeling for oral solution formulations in 2024, further highlight its expanding role.

Regulatory History

Colchicine received its initial U.S. Food and Drug Administration (FDA) approval in 1961 as a component of the combination product Col-Benemid (colchicine 0.5 mg with probenecid 500 mg) for the treatment of gout. In 2009, the FDA approved Colcrys as the first single-ingredient oral colchicine formulation (0.6 mg tablets) for the prophylaxis and treatment of acute gout flares and for familial Mediterranean fever (FMF), granting it orphan drug exclusivity for the FMF indication due to the disease's rarity. This approval occurred amid the FDA's Unapproved Drugs Initiative, which required the withdrawal of unapproved colchicine products by 2010, effectively creating a market monopoly for Colcrys and resulting in a price surge from approximately $0.09 per tablet to $5 per tablet. The Colcrys approval sparked significant from 2006 to 2015, as the manufacturer, Mutual Pharmaceutical (later acquired by Takeda), pursued litigations and exclusivity periods that delayed generic entry, leading to antitrust lawsuits and criticism over access barriers for patients with and FMF. To address the drug's narrow and risk of severe , including fatal overdoses, the FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) for Colcrys in 2009, requiring medication guides for patients and healthcare providers to emphasize drug interactions, dosing limits, and symptoms. In , colchicine has long been authorized through national marketing approvals in member states for the treatment of acute gout flares, gout prophylaxis, and FMF, with the (EMA) issuing product-specific bioequivalence guidance in 2019 for 0.5 mg and 1 mg tablets to standardize generics. It is classified as a prescription-only across the , reflecting its controlled status due to toxicity concerns, similar to Schedule 4 substances in other jurisdictions like . Globally, colchicine appeared on the World Health Organization (WHO) Model List of from 1977 until its removal in 2005 for gout due to safer alternatives, though it remains essential for FMF in resource-limited settings. In response to 2000s poisonings—including approximately 112 deaths from oral colchicine reported to FDA MedWatch from 1983-2007, many linked to overdoses—many countries, including the U.S., , and , banned over-the-counter sales post-2008, mandating prescription-only status to curb accidental ingestions. As of 2025, regulatory updates include expanded guideline recommendations for low-dose colchicine (0.5 mg daily) in secondary prevention of atherosclerotic , following the FDA's 2023 approval of Lodoco for this indication based on the COLCOT and LoDoCo2 trials. International bodies, such as the , have harmonized dosing warnings in 2024 guidelines, emphasizing renal/hepatic adjustments and contraindications with /P-gp inhibitors to prevent toxicity, with additional approvals like an oral solution formulation for flare prevention in the U.S. in 2024.

Non-Medical Applications

Botanical Uses

Colchicine plays a significant role in botanical applications, particularly in and , where it is employed to induce by disrupting and preventing chromosome segregation during . This antimitotic action allows breeders to create polyploid plants with enhanced traits such as larger fruits, improved vigor, and sterility, which are valuable for commercial cultivation. The historical use of colchicine in botany dates back to the 1930s, when researchers like Albert Blakeslee and A.F. Blakeslee first demonstrated its efficacy in inducing tetraploids in crops such as , enabling the synthesis of hexaploid bread wheat through chromosome doubling of hybrids between tetraploid wheat and diploid Aegilops tauschii. This breakthrough facilitated the transfer of desirable traits like disease resistance and accelerated breeding programs for staple crops. In modern , colchicine is applied at concentrations typically ranging from 0.1% to 0.5% to treat seeds, seedlings, or explants, promoting that results in seedless fruits through the production of triploid hybrids. For instance, in breeding, diploid plants are treated with colchicine to generate tetraploids, which are then crossed with diploids to yield sterile triploid offspring that produce larger, seedless fruits with higher yields. Similarly, in (Musa spp.) cultivation, colchicine treatment of diploid seedlings or explants induces autotetraploids, aiding the development of seedless varieties with improved fruit quality and resistance to stresses. Horticultural applications extend to ornamental plants like (flame lily), where colchicine is used to induce for enhanced flower size, color intensity, and overall vigor, making it more appealing for garden and cut-flower markets. However, such treatments carry risks of plant toxicity, as excessive colchicine exposure can cause , , or lethality in sensitive species, necessitating precise dosing and monitoring to balance benefits against potential harm.

Research and Other Uses

Colchicine has been widely utilized in as a mitotic spindle poison that arrests cells in , facilitating visualization for karyotyping and the study of chromosomal abnormalities. By binding to and inhibiting polymerization, it prevents spindle formation, allowing accumulation of spreads essential for analyzing karyotypes in research on genetic disorders and species . This application extends to cancer studies, where colchicine induces models to investigate chromosomal instability in tumor cells. In anti-cancer research, colchicine's microtubule-targeting properties have prompted investigations into its potential as a chemotherapeutic agent, though clinical advancement has been hindered by systemic . Phase II trials of colchicine analogues, such as ZD6126, were terminated in the late 2000s due to severe , underscoring challenges in achieving therapeutic doses without adverse effects. Despite preclinical evidence of colchicine inducing in cancer cell lines like gastric carcinoma, its direct use remains limited, with ongoing efforts focused on derivatives to mitigate while preserving anti-proliferative efficacy. Beyond human applications, colchicine serves veterinary roles, particularly in treating in animals such as Shar-Pei dogs, where it helps prevent renal protein deposition associated with familial inflammatory conditions. In toxicology studies, elevated plasma colchicine concentrations act as a predictive for fatal outcomes in cases of acute poisoning, including from plant sources like , guiding prognostic assessments and supportive care. As of 2025, research frontiers include nanocarrier formulations for targeted colchicine delivery, which encapsulate the drug in polymeric nanoparticles to enhance , reduce off-target toxicity, and improve efficacy in conditions like through site-specific release. Additionally, approaches are being employed in structure-based to identify tubulin-targeting inhibitors, accelerating the development of novel compounds for therapeutic applications.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5812812/
  2. https://www.ncbi.nlm.nih.gov/books/NBK431102/
  3. https://medlineplus.gov/druginfo/meds/a682711.html
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215727s000lbl.pdf
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Colchicine
  6. https://doi.org/10.2174/1871526517666171017114901
  7. https://www.sciencedirect.com/science/article/abs/pii/S0223523419309407
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3884533/
  9. https://www.sigmaaldrich.com/US/en/product/sigma/c9754
  10. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6391144.htm
  11. https://doi.org/10.1007/s10953-010-9515-z
  12. https://www.inchem.org/documents/pims/pharm/colchic.htm
  13. https://www.tandfonline.com/doi/full/10.1080/28378083.2025.2476965
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7958869/
  15. https://www.nature.com/articles/s41467-023-44420-7
  16. https://pubs.acs.org/doi/10.1021/jacs.1c08659
  17. https://link.springer.com/article/10.1007/s00425-022-04003-0
  18. https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.202000633
  19. https://www.henriettes-herb.com/eclectic/usdisp/colchicum.html
  20. https://www.tandfonline.com/doi/full/10.1080/08327823.2019.1570450
  21. https://www.sciencedirect.com/science/article/abs/pii/S1433831911000266
  22. https://www.chicagobotanic.org/plant-collections/plant-finder/colchicum-autumnale-autumn-crocus
  23. https://www.anses.fr/en/content/confusion-between-autumn-crocus-and-wild-garlic-can-lead-fatal-poisoning
  24. https://www.sciencedirect.com/science/article/abs/pii/S030519780200248X
  25. https://link.springer.com/chapter/10.1007/978-3-540-74603-4_11
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7120738/
  27. https://exsyncorp.com/products/in-focus-colchicine-2/
  28. https://patents.google.com/patent/CN104610084B/en
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9663959/
  30. https://doi.org/10.3390/molecules24152772
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6681243/
  32. https://patents.google.com/patent/JPS63258589A/en
  33. https://www.sciencedirect.com/science/article/pii/S0149291814004573
  34. https://www.the-rheumatologist.org/article/colchicine-an-ancient-drug-with-modern-uses/?singlepage=1
  35. https://www.mayoclinic.org/drugs-supplements/colchicine-oral-route/description/drg-20067653
  36. https://www.uptodate.com/contents/gout-treatment-of-flares
  37. https://www.drugs.com/dosage/colchicine.html
  38. https://pubmed.ncbi.nlm.nih.gov/20131255/
  39. https://www.drugs.com/history/colcrys.html
  40. https://www.medicalindependent.ie/societies/isr/gout-management-in-2025/
  41. https://rmdopen.bmj.com/content/11/3/e006097
  42. https://ard.bmj.com/content/75/4/644
  43. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.788864/full
  44. https://academic.oup.com/rheumatology/article/53/10/1767/1816393
  45. https://www.nejm.org/doi/full/10.1056/NEJMoa1208536
  46. https://www.acpjournals.org/doi/10.7326/0003-4819-155-7-201110040-00359
  47. https://www.nejm.org/doi/full/10.1056/NEJMoa2021372
  48. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-low-dose-colchicine-prevent-cardiovascular-events-patients-coronary-artery-disease
  49. https://academic.oup.com/eurheartj/article/46/26/2552/8123897
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9323936/
  51. https://www.ncbi.nlm.nih.gov/books/NBK470257/
  52. https://pubmed.ncbi.nlm.nih.gov/7381068/
  53. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1327715/full
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8437891/
  55. https://www.medrxiv.org/content/10.1101/2025.04.04.25325283v1
  56. https://acrabstracts.org/abstract/safety-and-efficacy-of-colchicine-in-osteoarthritis-a-systematic-review-and-meta-analysis-of-6965-patients/
  57. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00065-6/abstract
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC8901563/
  59. https://pubs.acs.org/doi/10.1021/acsptsci.4c00730
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC4656054/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC4890167/
  62. https://www.ahajournals.org/doi/10.1161/JAHA.120.018993
  63. https://www.mdpi.com/1424-8247/13/1/8
  64. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204820Orig1s004lbl.pdf
  65. https://www.bmj.com/content/331/7517/613.1
  66. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022351lbl.pdf
  67. https://pubmed.ncbi.nlm.nih.gov/8035398/
  68. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf
  69. https://www.camberpharma.com/camber-launches-colchicine-capsules/
  70. https://www.federalregister.gov/documents/2008/02/08/08-564/drug-products-containing-colchicine-for-injection-enforcement-action-dates
  71. https://www.pharmacytimes.com/view/camber-launches-colchicine-capsules
  72. https://www.the-rheumatologist.org/article/fda-approves-oral-solution-of-colchicine-to-prevent-gout-flare/
  73. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC9754312/
  75. https://reference.medscape.com/drug/colcrys-mitigare-colchicine-342812
  76. https://www.medsafe.govt.nz/profs/PUArticles/March2025/Factors-contributing-to-colchicine-toxicity.html
  77. http://www.glowm.com/resources/glowm/cd/pages/drugs/c081.html
  78. https://www.pediatriconcall.com/drugs/colchicine/444
  79. https://www.ncbi.nlm.nih.gov/books/NBK501213/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941201/
  81. https://pubmed.ncbi.nlm.nih.gov/33399344/
  82. https://pubmed.ncbi.nlm.nih.gov/20586571/
  83. https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750016.html
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC10986813/
  85. https://pubmed.ncbi.nlm.nih.gov/11474292/
  86. https://pubmed.ncbi.nlm.nih.gov/10802421/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC8298785/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC6943411/
  89. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056171
  90. https://www.poison.org/-/media/files/aapcc-annual-reports/npds2020.pdf
  91. https://academic.oup.com/rheumatology/article/63/4/936/7455266
  92. https://pubmed.ncbi.nlm.nih.gov/39688840/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC9417090/
  94. https://apjmt.mums.ac.ir/article_12293.html
  95. https://www.tandfonline.com/doi/full/10.1080/15563650.2023.2268981
  96. https://pubmed.ncbi.nlm.nih.gov/15311853/
  97. https://www.the-rheumatologist.org/article/colchicine-an-ancient-drug-with-modern-uses/
  98. https://scispace.com/pdf/history-of-the-use-of-colchicum-and-related-medicaments-in-1826ulqmts.pdf
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC7046033/
  100. https://www.sl.nsw.gov.au/sites/default/files/kill_or_cure_pamphlets.pdf
  101. https://pubmed.ncbi.nlm.nih.gov/29336251/
  102. https://www.nature.com/articles/155141d0
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC286251/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC1934591/
  105. https://www.nature.com/articles/ng0997-25
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC8767044/
  107. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_MedR.pdf
  108. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information
  109. https://www.the-rheumatologist.org/article/colchicine-an-ancient-drug-with-modern-uses/7/?singlepage=1
  110. https://www.medpagetoday.com/rheumatology/generalrheumatology/89927
  111. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_REMS.pdf
  112. https://www.ema.europa.eu/en/documents/scientific-guideline/colchicine-tablet-05-mg-1-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf
  113. https://list.essentialmeds.org/medicines/537
  114. https://www.researchgate.net/publication/51477810_Unrecognized_fatalities_related_to_colchicine_in_hospitalized_patients
  115. https://www.federalregister.gov/documents/2010/10/01/2010-24684/single-ingredient-oral-colchicine-products-enforcement-action-dates
  116. https://www.uspharmacist.com/article/colchicine-use-in-atherosclerotic-cardiovascular-disease
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC12294850/
  118. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2020.00722/full
  119. https://www.k-state.edu/wgrc/publications/2006/8655.pdf
  120. https://www.sciencedirect.com/science/article/abs/pii/S0926669017307604
  121. https://cucurbitbreeding.wordpress.ncsu.edu/watermelon-breeding/seedless-watermelon-breeding/
  122. https://www.ishs.org/ishs-article/502_27
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC10607973/
  124. https://home.cc.umanitoba.ca/~frist/PLNT3140/l04/l04.html
  125. https://www.tandfonline.com/doi/pdf/10.1080/00087114.1974.10796589
  126. https://pubmed.ncbi.nlm.nih.gov/2398818/
  127. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087064
  128. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1528235/full
  129. https://www.wedgewood.com/medications/colchicine/
  130. https://www.tandfonline.com/doi/abs/10.1080/15563650.2019.1581939
  131. https://www.nature.com/articles/s41598-025-16131-0
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.